NO301234B1 - Fremgangsmåte for fremstilling av et glycosylert eller ikke-glycosylert polypeptid som utviser human-interleukin-4-aktivitet, nukleinsyre og vektor - Google Patents
Fremgangsmåte for fremstilling av et glycosylert eller ikke-glycosylert polypeptid som utviser human-interleukin-4-aktivitet, nukleinsyre og vektor Download PDFInfo
- Publication number
- NO301234B1 NO301234B1 NO872988A NO872988A NO301234B1 NO 301234 B1 NO301234 B1 NO 301234B1 NO 872988 A NO872988 A NO 872988A NO 872988 A NO872988 A NO 872988A NO 301234 B1 NO301234 B1 NO 301234B1
- Authority
- NO
- Norway
- Prior art keywords
- cells
- activity
- group
- sequence
- cell
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 88
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 87
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 25
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 23
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 23
- 230000000694 effects Effects 0.000 title claims description 199
- 229920001184 polypeptide Polymers 0.000 title claims description 85
- 238000000034 method Methods 0.000 title claims description 73
- 239000013598 vector Substances 0.000 title claims description 65
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 title claims description 61
- 102000055229 human IL4 Human genes 0.000 title claims description 60
- 230000001747 exhibiting effect Effects 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title description 20
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract description 99
- 102000004388 Interleukin-4 Human genes 0.000 claims abstract description 97
- 239000000427 antigen Substances 0.000 claims abstract description 34
- 108091007433 antigens Proteins 0.000 claims abstract description 34
- 102000036639 antigens Human genes 0.000 claims abstract description 34
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 229940028885 interleukin-4 Drugs 0.000 claims abstract description 5
- 239000002299 complementary DNA Substances 0.000 claims description 101
- 108090000623 proteins and genes Proteins 0.000 claims description 84
- 102000004169 proteins and genes Human genes 0.000 claims description 64
- 230000014509 gene expression Effects 0.000 claims description 56
- 150000001413 amino acids Chemical class 0.000 claims description 31
- 239000002773 nucleotide Substances 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 28
- 230000006698 induction Effects 0.000 claims description 25
- 238000010276 construction Methods 0.000 claims description 18
- 238000003780 insertion Methods 0.000 claims description 15
- 230000037431 insertion Effects 0.000 claims description 15
- 108020004705 Codon Proteins 0.000 claims description 10
- 210000003714 granulocyte Anatomy 0.000 claims description 8
- FBHOPGDGELNWRH-DRZSPHRISA-N Ala-Glu-Phe Chemical group [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O FBHOPGDGELNWRH-DRZSPHRISA-N 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical group [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 claims description 2
- 241000024188 Andala Species 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 230000002730 additional effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 277
- 239000006228 supernatant Substances 0.000 description 151
- 108010002350 Interleukin-2 Proteins 0.000 description 142
- 102000000588 Interleukin-2 Human genes 0.000 description 142
- 108010002386 Interleukin-3 Proteins 0.000 description 121
- 102100039064 Interleukin-3 Human genes 0.000 description 121
- 108020004635 Complementary DNA Proteins 0.000 description 112
- 238000010804 cDNA synthesis Methods 0.000 description 97
- 239000012634 fragment Substances 0.000 description 80
- 210000003719 b-lymphocyte Anatomy 0.000 description 69
- 210000001744 T-lymphocyte Anatomy 0.000 description 66
- 229940076264 interleukin-3 Drugs 0.000 description 64
- 239000013612 plasmid Substances 0.000 description 62
- 235000018102 proteins Nutrition 0.000 description 61
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 58
- 108010039445 Stem Cell Factor Proteins 0.000 description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 55
- 108020004414 DNA Proteins 0.000 description 44
- 241001529936 Murinae Species 0.000 description 38
- 239000000203 mixture Substances 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 238000003556 assay Methods 0.000 description 30
- 230000032823 cell division Effects 0.000 description 30
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 29
- 239000011780 sodium chloride Substances 0.000 description 29
- 239000000523 sample Substances 0.000 description 27
- 241000588724 Escherichia coli Species 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 26
- 210000003630 histaminocyte Anatomy 0.000 description 25
- 238000000746 purification Methods 0.000 description 25
- 102000008072 Lymphokines Human genes 0.000 description 23
- 108010074338 Lymphokines Proteins 0.000 description 23
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 22
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 239000012894 fetal calf serum Substances 0.000 description 21
- 239000002609 medium Substances 0.000 description 20
- 108020004999 messenger RNA Proteins 0.000 description 20
- 239000008188 pellet Substances 0.000 description 20
- 238000001890 transfection Methods 0.000 description 20
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 19
- 230000004071 biological effect Effects 0.000 description 19
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 18
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 18
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 18
- 238000010790 dilution Methods 0.000 description 18
- 239000012895 dilution Substances 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 18
- 201000005484 prostate carcinoma in situ Diseases 0.000 description 18
- 102000009438 IgE Receptors Human genes 0.000 description 17
- 108010073816 IgE Receptors Proteins 0.000 description 17
- 238000009396 hybridization Methods 0.000 description 17
- 238000010561 standard procedure Methods 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 108010062580 Concanavalin A Proteins 0.000 description 16
- 108010047620 Phytohemagglutinins Proteins 0.000 description 16
- 230000001885 phytohemagglutinin Effects 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 230000001419 dependent effect Effects 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 13
- 230000010076 replication Effects 0.000 description 13
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 13
- 241000282693 Cercopithecidae Species 0.000 description 12
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000007792 addition Methods 0.000 description 12
- 238000010367 cloning Methods 0.000 description 12
- 238000010828 elution Methods 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 12
- 108091008146 restriction endonucleases Proteins 0.000 description 12
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 12
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 241001646716 Escherichia coli K-12 Species 0.000 description 10
- 101100232919 Homo sapiens IL4 gene Proteins 0.000 description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 10
- 210000002443 helper t lymphocyte Anatomy 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 102000004594 DNA Polymerase I Human genes 0.000 description 9
- 108010017826 DNA Polymerase I Proteins 0.000 description 9
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 9
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 9
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 9
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 9
- 102000000589 Interleukin-1 Human genes 0.000 description 9
- 108010002352 Interleukin-1 Proteins 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 108020001096 dihydrofolate reductase Proteins 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 238000010348 incorporation Methods 0.000 description 9
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 9
- 230000000644 propagated effect Effects 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 238000009738 saturating Methods 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 238000005277 cation exchange chromatography Methods 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 210000002741 palatine tonsil Anatomy 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 7
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 229960000723 ampicillin Drugs 0.000 description 7
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 7
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000007398 colorimetric assay Methods 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000005194 fractionation Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000010369 molecular cloning Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000000284 resting effect Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 239000001226 triphosphate Substances 0.000 description 7
- 235000011178 triphosphate Nutrition 0.000 description 7
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 6
- 239000005695 Ammonium acetate Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 241000276498 Pollachius virens Species 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 235000019257 ammonium acetate Nutrition 0.000 description 6
- 229940043376 ammonium acetate Drugs 0.000 description 6
- -1 below 10 Chemical class 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 239000013600 plasmid vector Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000003226 mitogen Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 210000005253 yeast cell Anatomy 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010061982 DNA Ligases Proteins 0.000 description 4
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 4
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000000743 Interleukin-5 Human genes 0.000 description 4
- 108010002616 Interleukin-5 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 108091036060 Linker DNA Proteins 0.000 description 4
- 101001033276 Mus musculus Interleukin-3 Proteins 0.000 description 4
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 108700005078 Synthetic Genes Proteins 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000005341 cation exchange Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940047120 colony stimulating factors Drugs 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 229960004198 guanidine Drugs 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000009696 proliferative response Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- RDZTWEVXRGYCFV-UHFFFAOYSA-M sodium 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonate Chemical compound [Na+].OCCN1CCN(CCS([O-])(=O)=O)CC1 RDZTWEVXRGYCFV-UHFFFAOYSA-M 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000010474 transient expression Effects 0.000 description 4
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 3
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000003302 anti-idiotype Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 101150042295 arfA gene Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000011098 chromatofocusing Methods 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960002086 dextran Drugs 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000012757 fluorescence staining Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 229940079938 nitrocellulose Drugs 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 101150087557 omcB gene Proteins 0.000 description 3
- 101150115693 ompA gene Proteins 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LTFMZDNNPPEQNG-KVQBGUIXSA-N 2'-deoxyguanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 LTFMZDNNPPEQNG-KVQBGUIXSA-N 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- 101001002717 Bos taurus Interleukin-4 Proteins 0.000 description 2
- 101000932768 Conus catus Alpha-conotoxin CIC Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 2
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 241000269368 Xenopus laevis Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000013014 purified material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 101150037435 tnaB gene Proteins 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 101150008346 trpP gene Proteins 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AVKUERGKIZMTKX-BBGACYKPSA-N (2s,5r,6r)-6-[[(2s)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound C1([C@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-BBGACYKPSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 description 1
- AENZGWONVTXLRC-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1N1C(=O)C=CC1=O AENZGWONVTXLRC-UHFFFAOYSA-N 0.000 description 1
- OQPDPIPLWCUACY-UHFFFAOYSA-N 2-aminoethylthiourea;hydrobromide Chemical compound [Br-].NCC[NH+]=C(N)S OQPDPIPLWCUACY-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZPBWLZAKZOHLOP-UHFFFAOYSA-N 5-(1-hydroxyethyl)-3-phenyl-2-sulfanylideneimidazolidin-4-one Chemical compound O=C1C(C(O)C)NC(=S)N1C1=CC=CC=C1 ZPBWLZAKZOHLOP-UHFFFAOYSA-N 0.000 description 1
- MFCDHQNPTNBIGC-UHFFFAOYSA-N 6-diazocyclohexa-2,4-diene-1-carboxylic acid Chemical compound OC(=O)C1C=CC=CC1=[N+]=[N-] MFCDHQNPTNBIGC-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000409811 Bombyx mori nucleopolyhedrovirus Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 108010089133 GGTACC-specific type II deoxyribonucleases Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102100020941 Interleukin-4 Human genes 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100438957 Mus musculus Cd8a gene Proteins 0.000 description 1
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 1
- 101000934342 Mus musculus T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003532 endogenous pyrogen Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010092809 exonuclease Bal 31 Proteins 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 108040006856 interleukin-3 receptor activity proteins Proteins 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002093 isoelectric focusing polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 108010052620 leukocyte endogenous mediator Proteins 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000015929 positive regulation of B cell proliferation Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 244000195895 saibo Species 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000013606 secretion vector Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 101150108727 trpl gene Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16241—Use of virus, viral particle or viral elements as a vector
- C12N2710/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Fertilizers (AREA)
- Auxiliary Devices For Music (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79966985A | 1985-11-19 | 1985-11-19 | |
| US79966885A | 1985-11-19 | 1985-11-19 | |
| US06/843,958 US5552304A (en) | 1985-11-19 | 1986-03-25 | CDNA Clones coding for human protein exhibiting a broad cellular activity spectrum (human interleukin-4) |
| US88155386A | 1986-07-03 | 1986-07-03 | |
| US06/908,215 US5017691A (en) | 1986-07-03 | 1986-09-17 | Mammalian interleukin-4 |
| PCT/US1986/002464 WO1987002990A1 (en) | 1985-11-19 | 1986-11-19 | Mammalian interleukin-4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO872988D0 NO872988D0 (no) | 1987-07-17 |
| NO872988L NO872988L (no) | 1987-09-18 |
| NO301234B1 true NO301234B1 (no) | 1997-09-29 |
Family
ID=27542219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO872988A NO301234B1 (no) | 1985-11-19 | 1987-07-17 | Fremgangsmåte for fremstilling av et glycosylert eller ikke-glycosylert polypeptid som utviser human-interleukin-4-aktivitet, nukleinsyre og vektor |
Country Status (23)
| Country | Link |
|---|---|
| EP (3) | EP0230107A1 (xx) |
| JP (2) | JP2557361B2 (xx) |
| KR (1) | KR940007773B1 (xx) |
| CN (1) | CN1020472C (xx) |
| AT (2) | ATE140009T1 (xx) |
| AU (1) | AU610057B2 (xx) |
| CZ (1) | CZ414191A3 (xx) |
| DE (2) | DE3650538T2 (xx) |
| DK (1) | DK371087A (xx) |
| ES (2) | ES2153444T3 (xx) |
| FI (1) | FI102075B1 (xx) |
| GR (1) | GR3021198T3 (xx) |
| HK (2) | HK1005594A1 (xx) |
| HU (1) | HU208710B (xx) |
| IE (1) | IE80828B1 (xx) |
| IL (1) | IL80678A (xx) |
| MY (1) | MY101972A (xx) |
| NO (1) | NO301234B1 (xx) |
| NZ (1) | NZ218332A (xx) |
| OA (1) | OA08947A (xx) |
| PT (1) | PT83761B (xx) |
| SK (1) | SK414191A3 (xx) |
| WO (1) | WO1987002990A1 (xx) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0740943B2 (ja) * | 1985-09-30 | 1995-05-10 | 佑 本庶 | 新規なポリペプチドをコードするｄｎａ及びその製造方法 |
| US5912136A (en) * | 1985-11-19 | 1999-06-15 | Schering Corporation | Monoclonal antibodies against human interleukin-4 and hybridomas producing the same |
| US5700915A (en) * | 1985-11-19 | 1997-12-23 | Schering Corporations | Human interleukin immunopurification processes |
| US5041381A (en) * | 1986-07-03 | 1991-08-20 | Schering Corporation | Monoclonal antibodies against human interleukin-4 and hybridomas producing the same |
| US5082927A (en) * | 1986-09-24 | 1992-01-21 | The United States Of America As Represented By The Department Of Health And Human Services | Selectively cytotoxic IL-4-PE40 fusion protein |
| AU620537B2 (en) * | 1986-12-19 | 1992-02-20 | Immunex Corporation | Human interleukin-4 muteins |
| SE8701004D0 (sv) * | 1987-03-11 | 1987-03-11 | Astra Ab | Method for therapy of leukemias and certain other malignancies |
| WO1989001046A1 (en) * | 1987-07-29 | 1989-02-09 | Schering Biotech Corporation | Purification of human interleukin-4 expressed in escherichia coli |
| JPH02485A (ja) * | 1987-08-03 | 1990-01-05 | Yuu Honshiyo | 新規なヒトインターロイキン４、該因子を発現させるための組換えベクター及びそのベクターにより形質転換された形質転換体 |
| DE3882611T2 (de) * | 1987-08-03 | 1993-12-23 | Tasuku Honjo | Menschliches Interleukin-4, Expressionsvektoren dafür und diese enthaltende Transformanten. |
| ES2058490T3 (es) * | 1988-02-02 | 1994-11-01 | Schering Biotech Corp | Metodo de reducir respuestas de inmunoglobulina e. |
| GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
| GB2218420B (en) * | 1988-04-12 | 1992-07-15 | British Bio Technology | Synthetic gene encoding interleukin 4 |
| WO1989010939A1 (en) * | 1988-05-13 | 1989-11-16 | University Patents, Inc. | Immunogens and biologically active peptides derived from shared sequences from antigens and anti-idiotypic antibodies or antibodies specific for cellular receptors of the antigens |
| US4958007A (en) * | 1988-05-17 | 1990-09-18 | Schering-Plough Corp. | Extraction of human interleukin-4- from bacteria |
| AU643427B2 (en) * | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| WO1990006765A1 (en) * | 1988-12-21 | 1990-06-28 | Schering Corporation | Use of interleukin-4 for lowering blood glucose levels and/or effecting weight reduction |
| WO1990007932A1 (en) * | 1989-01-20 | 1990-07-26 | The University Of Melbourne | Fibrinolysis |
| US5077388A (en) * | 1990-05-31 | 1991-12-31 | Schering Corporation | Purification of human interleukin-4 from a secreted escherichia coli mutant |
| WO1991007186A1 (en) * | 1989-11-21 | 1991-05-30 | The University Of Melbourne | Anti-inflammatory compositions and methods |
| SE465039B (sv) * | 1989-11-23 | 1991-07-15 | Chemrec Ab | Saett att framstaella koklutar med hoeg sulfiditet foer sulfatmassakokning |
| US5188827A (en) * | 1989-12-18 | 1993-02-23 | Schering Corporation | Use of interleukin-4- for lowering blood-cholesterol levels |
| IL96714A0 (en) | 1989-12-20 | 1991-09-16 | Schering Corp | Antibody antagonists of human interleukin-4 |
| CA2078676A1 (en) * | 1990-03-21 | 1991-09-22 | Jerome Schwartz | Use of il-4 to enhance immune response to infectious antigenic challenges |
| EP0563254B1 (en) * | 1990-12-19 | 1995-11-08 | Schering Corporation | Use of il-4 to enhance immune response to immunogens in vaccines |
| ATE135233T1 (de) * | 1991-01-10 | 1996-03-15 | Schering Corp | Verwendung von il-4 zur verstärkung von wundheilung und besserung und zur heilung von infizierten wunden und wunden bei diabetischen säugetieren |
| US5494662A (en) * | 1992-04-27 | 1996-02-27 | Ono Pharmaceutical Co., Ltd. | Stimulator for bone formation |
| US5716612A (en) * | 1994-09-07 | 1998-02-10 | Schering Corporation | Use of IL-4 for potentiation of chemotherapeutic agents |
| AUPN481295A0 (en) * | 1995-08-16 | 1995-09-07 | Medvet Science Pty. Ltd. | Agonists of haemopoietic growth factors |
| US6335426B1 (en) | 1996-06-14 | 2002-01-01 | Bayer Corporation | T-cell selective interleukin-4 agonists |
| US5986059A (en) * | 1996-06-14 | 1999-11-16 | Bayer Corporation | T-cell selective interleukin-4 agonists |
| US6028176A (en) | 1996-07-19 | 2000-02-22 | Bayer Corporation | High-affinity interleukin-4 muteins |
| CA2331726C (en) * | 1998-05-12 | 2010-03-09 | Isis Pharmaceuticals Inc. | Modulation of molecular interaction sites on rna and other biomolecules |
| AUPQ005399A0 (en) * | 1999-04-29 | 1999-05-27 | Medvet Science Pty. Ltd. | Agonists or antagonists for haemopoietic growth factors |
| LT2665486T (lt) | 2011-01-18 | 2020-04-10 | Bioniz, Llc | Kompozicijos, skirtos gama-c-citokino aktyvumui moduliuoti |
| WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| CN102212888A (zh) * | 2011-03-17 | 2011-10-12 | 靳海峰 | 一种基于高通量测序的免疫组库构建方法 |
| US11400134B2 (en) | 2015-10-09 | 2022-08-02 | Bioniz, Llc | Modulating gamma-c-cytokine activity |
| WO2020227019A1 (en) | 2019-05-03 | 2020-11-12 | Bioniz, Llc | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US799668A (en) * | 1905-05-29 | 1905-09-19 | Albert R Pritchard | Dough kneader and mixer. |
| US799669A (en) * | 1905-07-27 | 1905-09-19 | Eugene S Regnier | Combined cutting and raking implement. |
| US843958A (en) * | 1905-11-20 | 1907-02-12 | Whitehead & Hoag Co | Key-ring tag. |
| US4613459A (en) * | 1982-10-20 | 1986-09-23 | Dana-Farber Cancer Institute | Lymphocyte growth factor |
| US4695542A (en) * | 1983-10-04 | 1987-09-22 | Dnax Research Institute Of Molecular And Cellular Biology, Inc. | cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity |
| WO1987004723A1 (en) * | 1986-02-11 | 1987-08-13 | Board Of Regents, The University Of Texas System | Recombinant human b-cell growth factor |
| ZA872781B (en) * | 1986-05-19 | 1987-10-05 | Immunology Ventures | B-cell stimulating factor |
| AU620537B2 (en) * | 1986-12-19 | 1992-02-20 | Immunex Corporation | Human interleukin-4 muteins |
-
1986
- 1986-11-18 PT PT83761A patent/PT83761B/pt not_active IP Right Cessation
- 1986-11-18 IL IL8067886A patent/IL80678A/en active IP Right Grant
- 1986-11-19 CN CN86108579A patent/CN1020472C/zh not_active Expired - Lifetime
- 1986-11-19 NZ NZ218332A patent/NZ218332A/xx unknown
- 1986-11-19 AT AT86907184T patent/ATE140009T1/de not_active IP Right Cessation
- 1986-11-19 EP EP86309041A patent/EP0230107A1/en active Pending
- 1986-11-19 AU AU67334/87A patent/AU610057B2/en not_active Ceased
- 1986-11-19 ES ES95108150T patent/ES2153444T3/es not_active Expired - Lifetime
- 1986-11-19 IE IE304286A patent/IE80828B1/en not_active IP Right Cessation
- 1986-11-19 ES ES86907184T patent/ES2088858T3/es not_active Expired - Lifetime
- 1986-11-19 DE DE3650538T patent/DE3650538T2/de not_active Expired - Lifetime
- 1986-11-19 JP JP61506135A patent/JP2557361B2/ja not_active Expired - Lifetime
- 1986-11-19 AT AT95108150T patent/ATE198754T1/de not_active IP Right Cessation
- 1986-11-19 HU HU865547A patent/HU208710B/hu not_active IP Right Cessation
- 1986-11-19 EP EP95108150A patent/EP0675136B1/en not_active Expired - Lifetime
- 1986-11-19 EP EP86907184A patent/EP0249613B1/en not_active Expired - Lifetime
- 1986-11-19 DE DE3650751T patent/DE3650751T2/de not_active Expired - Lifetime
- 1986-11-19 WO PCT/US1986/002464 patent/WO1987002990A1/en active IP Right Grant
-
1987
- 1987-07-16 DK DK371087A patent/DK371087A/da not_active Application Discontinuation
- 1987-07-16 FI FI873141A patent/FI102075B1/fi not_active IP Right Cessation
- 1987-07-17 NO NO872988A patent/NO301234B1/no not_active IP Right Cessation
- 1987-07-17 OA OA59167A patent/OA08947A/xx unknown
- 1987-08-10 MY MYPI87001250A patent/MY101972A/en unknown
-
1991
- 1991-12-30 SK SK4141-91A patent/SK414191A3/sk unknown
- 1991-12-30 CZ CS914141A patent/CZ414191A3/cs unknown
-
1993
- 1993-01-21 KR KR1019930000857A patent/KR940007773B1/ko not_active IP Right Cessation
-
1995
- 1995-08-25 JP JP7217072A patent/JP2568394B2/ja not_active Expired - Lifetime
-
1996
- 1996-09-30 GR GR960402553T patent/GR3021198T3/el unknown
-
1998
- 1998-06-02 HK HK98104741A patent/HK1005594A1/xx not_active IP Right Cessation
- 1998-07-29 HK HK98109519A patent/HK1008823A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0675136B1 (en) | Antibodies to mammalian interleukin-4 and peptides useful as antigens in their production | |
| US5017691A (en) | Mammalian interleukin-4 | |
| Yokota et al. | Isolation and characterization of lymphokine cDNA clones encoding mouse and human IgA-enhancing factor and eosinophil colony-stimulating factor activities: relationship to interleukin 5. | |
| EP0282185A1 (en) | Human interleukin-3 and muteins thereof | |
| JP4230659B2 (ja) | ケモカインアンタゴニストとしてのアミノ末端切除型ｍｃｐ−２ | |
| KR19990063653A (ko) | 케모킨 억제제 | |
| CA1335717C (en) | Human granulocyte-macrophage colony stimulating factor and muteins thereof | |
| US5955315A (en) | Nucleic acids encoding human interleukin-4 | |
| US5730970A (en) | Pharmaceutical compositions comprising human interleukin-4 (IL-4) | |
| CA1341299C (en) | Mammalian interleukin-4 | |
| KR930009084B1 (ko) | 포유동물의 인터로이킨-4, 이를 포함하는 조성물 및 이의 제조방법 | |
| US5807996A (en) | Fused polypeptides comprising interleukin-4 polypeptide fragments | |
| EP0267779A2 (en) | Human pleiotropic immune factor and muteins thereof | |
| AU2131688A (en) | Human granulocyte-macrophage colony stimulating factor and muteins thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN MAY 2003 |